These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 33025002)

  • 21. Breast cancer, endometrial cancer, and cardiovascular events in participants who used vaginal estrogen in the Women's Health Initiative Observational Study.
    Crandall CJ; Hovey KM; Andrews CA; Chlebowski RT; Stefanick ML; Lane DS; Shifren J; Chen C; Kaunitz AM; Cauley JA; Manson JE
    Menopause; 2018 Jan; 25(1):11-20. PubMed ID: 28816933
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Estrogen plus progestin therapy and breast cancer in recently postmenopausal women.
    Prentice RL; Chlebowski RT; Stefanick ML; Manson JE; Pettinger M; Hendrix SL; Hubbell FA; Kooperberg C; Kuller LH; Lane DS; McTiernan A; Jo O'Sullivan M; Rossouw JE; Anderson GL
    Am J Epidemiol; 2008 May; 167(10):1207-16. PubMed ID: 18372396
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effects of estrogen plus progestin on gynecologic cancers and associated diagnostic procedures: the Women's Health Initiative randomized trial.
    Anderson GL; Judd HL; Kaunitz AM; Barad DH; Beresford SA; Pettinger M; Liu J; McNeeley SG; Lopez AM;
    JAMA; 2003 Oct; 290(13):1739-48. PubMed ID: 14519708
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Menopausal Hormone Therapy and Ovarian and Endometrial Cancers: Long-Term Follow-Up of the Women's Health Initiative Randomized Trials.
    Chlebowski RT; Aragaki AK; Pan K; Haque R; Rohan TE; Song M; Wactawski-Wende J; Lane DS; Harris HR; Strickler H; Kauntiz AM; Runowicz CD
    J Clin Oncol; 2024 Oct; 42(30):3537-3549. PubMed ID: 39173088
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effect of estrogen plus progestin on global cognitive function in postmenopausal women: the Women's Health Initiative Memory Study: a randomized controlled trial.
    Rapp SR; Espeland MA; Shumaker SA; Henderson VW; Brunner RL; Manson JE; Gass ML; Stefanick ML; Lane DS; Hays J; Johnson KC; Coker LH; Dailey M; Bowen D;
    JAMA; 2003 May; 289(20):2663-72. PubMed ID: 12771113
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Estrogen alone and health outcomes in black women by African ancestry: a secondary analyses of a randomized controlled trial.
    Chlebowski RT; Barrington W; Aragaki AK; Manson JE; Sarto G; OʼSullivan MJ; Wu D; Cauley JA; Qi L; Wallace RL; Prentice RL
    Menopause; 2017 Feb; 24(2):133-141. PubMed ID: 27749739
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Menopausal Hormone Therapy and Risks of First Hospitalized Heart Failure and its Subtypes During the Intervention and Extended Postintervention Follow-up of the Women's Health Initiative Randomized Trials.
    Liu L; Klein L; Eaton C; Panjrath G; Martin LW; Chae CU; Greenland P; Lloyd-Jones DM; Wactawski-Wende J; Manson JE
    J Card Fail; 2020 Jan; 26(1):2-12. PubMed ID: 31536806
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Combined postmenopausal hormone therapy and cardiovascular disease: toward resolving the discrepancy between observational studies and the Women's Health Initiative clinical trial.
    Prentice RL; Langer R; Stefanick ML; Howard BV; Pettinger M; Anderson G; Barad D; Curb JD; Kotchen J; Kuller L; Limacher M; Wactawski-Wende J;
    Am J Epidemiol; 2005 Sep; 162(5):404-14. PubMed ID: 16033876
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Estrogen-plus-progestin use and mammographic density in postmenopausal women: Women's Health Initiative randomized trial.
    McTiernan A; Martin CF; Peck JD; Aragaki AK; Chlebowski RT; Pisano ED; Wang CY; Brunner RL; Johnson KC; Manson JE; Lewis CE; Kotchen JM; Hulka BS;
    J Natl Cancer Inst; 2005 Sep; 97(18):1366-76. PubMed ID: 16174858
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Women's Health Initiative clinical trials: potential interactive effect of calcium and vitamin D supplementation with hormonal therapy on cardiovascular disease.
    Jiang X; Nudy M; Aragaki AK; Robbins JA; Manson JE; Stefanick ML; OʼSullivan DM; Shikany JM; LeBlanc ES; Kelsey AM; Cauley J; Martin LW; Payne ME; Johnson KC; Howard B; Schnatz PF
    Menopause; 2019 Aug; 26(8):841-849. PubMed ID: 31145202
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Health risks outweigh benefits for combined estrogen plus progestin. Clinical trial stopped early in major study.
    American Medical Association
    Ginecol Obstet Mex; 2002 Aug; 70():411-2. PubMed ID: 12449905
    [No Abstract]   [Full Text] [Related]  

  • 32. Effects of estrogen with and without progestin on urinary incontinence.
    Hendrix SL; Cochrane BB; Nygaard IE; Handa VL; Barnabei VM; Iglesia C; Aragaki A; Naughton MJ; Wallace RB; McNeeley SG
    JAMA; 2005 Feb; 293(8):935-48. PubMed ID: 15728164
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Coronary heart disease events in the Women's Health Initiative hormone trials: effect modification by metabolic syndrome: a nested case-control study within the Women's Health Initiative randomized clinical trials.
    Wild RA; Wu C; Curb JD; Martin LW; Phillips L; Stefanick M; Trevisan M; Manson JE
    Menopause; 2013 Mar; 20(3):254-60. PubMed ID: 23435021
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The Women's Health Initiative trials of menopausal hormone therapy: lessons learned.
    Manson JE; Bassuk SS; Kaunitz AM; Pinkerton JV
    Menopause; 2020 Aug; 27(8):918-928. PubMed ID: 32345788
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Risks and benefits of menopausal hormone therapy in postmenopausal Chinese women.
    Su IH; Chen YC; Hwang WT; Liu Z; Su TP; Chen TJ; Barnhart KT; Yang YX
    Menopause; 2012 Aug; 19(8):931-41. PubMed ID: 22453198
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Conjugated equine estrogens and global cognitive function in postmenopausal women: Women's Health Initiative Memory Study.
    Espeland MA; Rapp SR; Shumaker SA; Brunner R; Manson JE; Sherwin BB; Hsia J; Margolis KL; Hogan PE; Wallace R; Dailey M; Freeman R; Hays J;
    JAMA; 2004 Jun; 291(24):2959-68. PubMed ID: 15213207
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause.
    Rossouw JE; Prentice RL; Manson JE; Wu L; Barad D; Barnabei VM; Ko M; LaCroix AZ; Margolis KL; Stefanick ML
    JAMA; 2007 Apr; 297(13):1465-77. PubMed ID: 17405972
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effects of postmenopausal hormone therapy on incident atrial fibrillation: the Women's Health Initiative randomized controlled trials.
    Perez MV; Wang PJ; Larson JC; Virnig BA; Cochrane B; Curb JD; Klein L; Manson JE; Martin LW; Robinson J; Wassertheil-Smoller S; Stefanick ML
    Circ Arrhythm Electrophysiol; 2012 Dec; 5(6):1108-16. PubMed ID: 23169946
    [TBL] [Abstract][Full Text] [Related]  

  • 39. New-onset breast tenderness after initiation of estrogen plus progestin therapy and breast cancer risk.
    Crandall CJ; Aragaki AK; Chlebowski RT; McTiernan A; Anderson G; Hendrix SL; Cochrane BB; Kuller LH; Cauley JA
    Arch Intern Med; 2009 Oct; 169(18):1684-91. PubMed ID: 19822825
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Coronary heart disease in postmenopausal recipients of estrogen plus progestin therapy: does the increased risk ever disappear? A randomized trial.
    Toh S; Hernández-Díaz S; Logan R; Rossouw JE; Hernán MA
    Ann Intern Med; 2010 Feb; 152(4):211-7. PubMed ID: 20157135
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.